Introduction:
Pharma stock has secured USFDA approval for its acetaminophen injection, strengthening its presence in the US generic injectables market. The product targets both adult and pediatric pain management, promising strong commercial potential with a USD 55 million addressable market.
Share Price movement of Gland Pharma:
On April 3, 2025, Gland Pharma Limited opened at ₹1,767.70, reaching a high of ₹1,767.70, up 8% from the previous close of ₹1,535.10, and a low of ₹1,541.60. The stock is currently trading at ₹1,571.00, with a market cap of ₹25,883.23 Crores.
Gland Pharma got approval from USFDA:
Gland Pharma Limited has received US FDA approval for its Acetaminophen Injection (10 mg/mL in 500mg/50mL and 1000mg/100mL bags). The product is therapeutically equivalent to B. Braun Medical’s formulation and is aimed at treating pain in both adults and pediatric patients above two years.
The injection is indicated for mild to moderate pain management, and for more severe pain when used along with opioid analgesics. The approved product expands Gland Pharma’s generic injectable portfolio and strengthens its regulatory presence in the US pharmaceutical market.
The company plans to commercialize the product shortly through its marketing partner. As per IQVIA data, the US market size for this injection stood at approximately USD 55 million for the twelve months ending February 2025, signaling healthy market potential.
Stock performance of Gland Pharma for Period of 1 week, 6 months and 1 year:
Over the past week, Gland Pharma’s stock dipped by 4.35%. In the last six months, it saw a decline of 12.2%, while over the one-year period, the stock posted a negative return of 14.1%, reflecting continued downward pressure on performance.
Shareholding pattern of Gland Pharma:
| All values in % | Dec-24 | Sep-24 | Jun-24 |
| Promoters | 51.83 | 51.83 | 51.83 |
| FII | 5.04 | 4.48 | 6.88 |
| DII | 34.8 | 35.37 | 32.83 |
| Retail & others | 8.33 | 8.33 | 8.46 |
Also Read: Alcohol stock hits 5% upper circuit after acquiring Solkit Distillery & Brewery Pvt Ltd for ₹13 Cr
About Gland Pharma:
Gland Pharma Ltd (NSE: GLAND) is a leading injectable-focused pharmaceutical company based in India. It manufactures and supplies complex injectables, oncology, and ophthalmic products globally, with strong capabilities in sterile operations and a presence across the U.S., Europe, and emerging markets.
Disclaimer: The above article is written for educational purposes, and the companies’ data mentioned in the article may change with respect to time The securities quoted are exemplary and are not recommendatory.
